Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever

Korean Journal of Internal Medicine

Volumn 21, Issue 3, 2006, Pages 165-172

  Park, Sun Hee ^a   Choi, Su Mi ^a   Lee, Dong Gun ^a   Choi, Jung Hyun ^a   Yoo, Jin Hong ^a   Min, Woo Sung ^a   Shin, Wan Shik ^a,b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Amphotericin B deoxycholate; Empirical antifungal therapy; Itraconazole; Persistent febrile neutropenia

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; HYDROCORTISONE; ITRACONAZOLE; POLYPEPTIDE ANTIBIOTIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANDIDIASIS; CASE CONTROL STUDY; CHILL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION PREVENTION; KOREA; LIVER TOXICITY; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; PERSISTENT INFECTION; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SINUSITIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SWEATING;

EID: 34948817348     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.3.165     Document Type: Article

References (24)

1. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39(Suppl 1):S38-S43, 2004
2. Marr KA. Empirical antifungal therapy: new options, new tradeoffs. N Engl J Med 346:278-280, 2002
3. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 23:105-112, 2004
4. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute for Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764-771, 1999
5. Yoo JH, Choi JH, Lee DG, Choi SM, Shin WS, Kim CC. Analysis of invasive fungal infection after hematopoietic stem cell transplantation or chemotherapy in patients with hematologic diseases. Infect Chemother 36:40-45, 2004
6. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111, 1982
7. The EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86:668-672, 1989
8. Karp JE, Merz WG, Charache P. Response to empiric amphotericin B during antileukemic therapy: induced granulocytopenia. Rev Infect Dis 13:592-599, 1991
9. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg H, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234, 2002
10. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402, 2004
11. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized controlled trial. Ann Intern Med 135:412-422, 2001
12. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 42:3018-3021, 1998
13. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 38:1530-1533, 1994
14. Bennett JE, Powers J, Walsh T, Viscoli C, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht H, Kauffman C, Lee J, Pappas F, Rex J, Verweij P. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 36(Suppl 3):S117-S122, 2003
15. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PD, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14, 2002
16. Pfaller MA, Diekemal DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:4419-4431, 2004
17. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108:282-289, 2000
18. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, Gurwith M, Miller CB. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296-302, 1998
19. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia: L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31:1155-1163, 2000
20. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26:561-566, 1990
21. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on antifungal susceptibility testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24:235-247, 1997
22. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrobial Chemother 56(Suppl 1):i17-i22, 2005
23. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrobial Chemother 56(Suppl 1):i33-i38, 2005
24. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103:1557-1559, 2004